FindTrial
Sign In

A randomized controlled trial for reproductive outcomes in HRT-FET cycles using Crinone 180 mg/day or 90 mg/day: a study based on Chinese population

Reproductive outcomes in HRT-FET cycles using Crinone 180 mg/day or 90 mg/day: a study based on Chinese population

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034113
Enrollment
Unknown
Registered
2020-06-24
Start date
2020-08-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

1:Crinone 180 mg/day
2:Crinone 90 mg/day plus dydrogesterone 20 mg/day.

Sponsors

Northwest Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. aged 20-40 years; 2. First cycle of HRT-FET; 3. thickness of endometrium>8mm; 4. Frozen Blastocyst >=2; 5. SET.

Exclusion criteria

Exclusion criteria: 1. Patients with RSA; 2. at least two failed cycles of ET; 3. Abnormal uterine; 4. hydrsalpines; 5. severe endometriosis; 6. PGT involved; 7. included by other clinical study; 8. drug contraindication (Crinone or dydrogesterone); 9. other medical diseases.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;—

Secondary

MeasureTime frame
rate of early pregnancy loss;—

Countries

China

Contacts

Public ContactJuanzishi

Northwest Women's and Children's Hospital

shijuanziart@126.com+86 13087519216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026